Ett nytt blodprov som mäter alzheimermarkören p-tau217 kan upptäcka sjukdomen upp till 20 år innan symtom uppträder, men läkare varnar för att friska personer som testar sig privat kan få felaktiga resultat, vilket ifrågasätter den säkra användningen av metoden. #Alzheimertest #pTau217 #Hälsa
Un test del sangue in grado di prevedere l'Alzheimer anni prima dei sintomi, identificando la proteina pTau217, è stato confermato come efficace anche nella popolazione asiatica da uno studio condotto dal National Neuroscience Institute e dalla Duke-NUS di Singapore. #Alzheimer #testdel sangue #neuroscienze
Roche announced that Elecsys pTau217, the first blood test designed to signal and rule out Alzheimer's disease, has received CE Mark clearance for use in Europe, offering a faster and simpler diagnostic tool for millions of patients and potentially reducing the burden on healthcare systems. #Alzheimers #BloodTest #HealthcareInnovation #EU #CH #US
Roche announced that Elecsys pTau217, the first blood test specifically designed to signal and rule out Alzheimer's disease, has received CE Mark approval for use in Europe, promising faster diagnoses for millions of patients by detecting pTau217 protein levels, thereby indicating the likelihood of Alzheimer's while potentially reducing the need for more invasive testing. #AlzheimersDisease #Diagnostics #HealthcareInnovation #EU #CH
Roche has received clearance for Elecsys pTau217, the first blood test designed to diagnose and rule out Alzheimer's disease in Europe, which promises faster diagnoses for millions of patients by detecting levels of a protein linked to the disease. #AlzheimersDisease #BloodTest #HealthcareInnovation #EU #CH #US
Roche has announced that the Elecsys pTau217 blood test, developed in collaboration with Eli Lilly and Company and now cleared for use in Europe, offers a rapid and effective method for diagnosing or ruling out Alzheimer's disease, potentially aiding millions of patients while reducing the burden on healthcare systems. #Alzheimers #BloodTest #Healthcare #EU #CH #US
Roche announced the European clearance of Elecsys pTau217, the first blood test designed to diagnose and rule out Alzheimer's disease, which offers a quicker diagnostic tool for millions of patients and aims to simplify the diagnostic process for physicians by indicating the likelihood of Alzheimer’s presence based on pTau217 protein levels. #Alzheimers #HealthcareInnovation #BloodTest #EU #CH #US
Roche announced the approval of Elecsys pTau217, the first blood test designed to signal and rule out Alzheimer's disease, which is now cleared for use in Europe, offering a faster and simpler diagnostic tool that can significantly improve early detection for patients and alleviate pressure on healthcare systems. #Alzheimers #BloodTest #HealthcareInnovation #EU #CH
Roche announced the clearance of Elecsys pTau217, the first blood test specifically designed to detect and rule out Alzheimer's disease, which is now authorized for use in Europe, promising faster diagnoses and improved support for patients and families navigating the challenges of the disease. #Alzheimers #Diagnostics #Healthcare #EU #CH #US
Testul de sânge Elecsys pTau217, recent aprobat în Uniunea Europeană, promite să faciliteze depistarea timpurie a bolii Alzheimer prin analiza anomaliilor proteice, oferind o metodă mai simplă și mai puțin invazivă decât procedurile actuale. #Alzheimer #testde sânge #diagnosticare #dobrezpravy
